Beta Bionics, Inc. - Common Stock (BBNX)
20.14
-11.85 (-37.04%)
NASDAQ · Last Trade: Jan 11th, 5:31 PM EST
Detailed Quote
| Previous Close | 31.99 |
|---|---|
| Open | 22.75 |
| Bid | 20.45 |
| Ask | 20.56 |
| Day's Range | 20.02 - 23.92 |
| 52 Week Range | 8.890 - 32.71 |
| Volume | 8,291,068 |
| Market Cap | - |
| PE Ratio (TTM) | -4.588 |
| EPS (TTM) | -4.4 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,297,274 |
Chart
News & Press Releases
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · January 10, 2026
What's going on in today's sessionchartmill.com
Via Chartmill · January 9, 2026
Keep an eye on the top gainers and losers in Friday's session.chartmill.com
Via Chartmill · January 9, 2026
The market is filled with gapping stocks in Friday's session.chartmill.com
Via Chartmill · January 9, 2026
Friday's pre-market session: top gainers and loserschartmill.com
Via Chartmill · January 9, 2026
Get insights into the top gainers and losers of Thursday's after-hours session.chartmill.com
Via Chartmill · January 8, 2026
IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025.
By Beta Bionics, Inc. · Via GlobeNewswire · January 8, 2026
IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026.
By Beta Bionics, Inc. · Via GlobeNewswire · December 8, 2025
Via Benzinga · November 10, 2025
IRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at two upcoming investor conferences (all Eastern Time):
By Beta Bionics, Inc. · Via GlobeNewswire · November 3, 2025
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · October 29, 2025
Beta Bionics (BBNX) Q3 2025 Earnings Transcript
Via The Motley Fool · October 29, 2025
Via Benzinga · October 29, 2025
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · October 28, 2025
Beta Bionics (BBNX) beat Q3 2025 revenue estimates and raised its full-year guidance. The medical device company reported strong user growth and a narrower-than-expected loss.
Via Chartmill · October 28, 2025
Via Benzinga · October 28, 2025
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year ending December 31, 2025.
By Beta Bionics, Inc. · Via GlobeNewswire · October 28, 2025
Via Benzinga · October 21, 2025
IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2025 financial results after the financial markets close on Tuesday, October 28, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time).
By Beta Bionics, Inc. · Via GlobeNewswire · October 9, 2025
Via Benzinga · October 1, 2025
IRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at three upcoming investor conferences (all Eastern Time):
By Beta Bionics, Inc. · Via GlobeNewswire · August 21, 2025